1. Scrip

Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer

 
• By Emily Hayes

Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.

OvarianCancer_1200x675

Tesaro Inc.'s Zejula (niraparib) may be the third PARP inhibitor to the US market, but it is positioned to seize the first-mover advantage for maintenance treatment of ovarian cancer, following a broad FDA approval for this indication, regardless of mutation status and without the need for a companion diagnostic.

Approval for the poly ADP-ribose polymerase inhibitor was announced March 27, well ahead of the drug's June 30 user fee date

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.